Biosplice Publishes Phase 2B Lorecivivint Analysis Showing Clinically Meaningful Benefits to Knee Osteoarthritis Patients
July 22, 2021 10:10 ET
|
Biosplice Therapeutics, Inc.
Lorecivivint post-hoc analysis reveals significantly increased likelihood of symptom improvements for knee osteoarthritis compared to placebo SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Biosplice...
Dave Johnson Joins Biosplice Therapeutics Board of Directors
June 21, 2021 09:15 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for...
Biosplice Publishes Successful Clinical Trial in Knee Osteoarthritis
April 26, 2021 09:15 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for...
Biosplice Licenses Rights to Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Samil for the Republic of Korea
April 22, 2021 11:36 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, April 22, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for...
Biotech Veterans Troy Cox, Susannah Gray and Karen McGinnis Join Biosplice Therapeutics Board of Directors
April 20, 2021 08:45 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for...